ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Tobacco Interests Contribute a Portion Of the $109 Million Raised by Stand Up To Cancer

September 12, 2014

Mendelsohn To Step Down As MD Anderson President

December 10, 2010

Grant Applications Pour Into NCI, NIH; Downward Trend In Funding Due To Be Reversed In FY 1979

June 16, 1978

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

November 29, 2013

DCPC Advisors Upset At NCAB Over Why Decision, But Move On

February 8, 1991

Simone Replaces Levine As Cancer Policy Board Chairman

April 19, 2002